Lenvatinib Mesylate and Measles virus vaccine, live Subcutaneous
Determining the interaction of Lenvatinib Mesylate and Measles virus vaccine, live Subcutaneous and the possibility of their joint administration.
No interaction was detected between the selected drugs or effects of joint drug administration are currently understudied, and it takes time and accumulated statistics to determine their interaction. A doctor should be consulted to address the issue of joint drug administration.
Generic Name: lenvatinib
Brand name: Lenvima, Lenvima 8 mg daily-dose, Lenvima 20 mg daily-dose, Lenvima 12 mg daily-dose
Synonyms: Lenvatinib
Generic Name: measles virus vaccine
Brand name:
Synonyms: Measles virus vaccine, live (Subcutaneous)
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Lenvatinib Mesylate-Measles, mumps, and rubella (MMR) vaccine
- Lenvatinib Mesylate-Measles, Mumps, and Rubella Vaccine
- Lenvatinib Mesylate-Measles, Mumps, and Rubella Virus Vaccine
- Lenvatinib Mesylate-Measles, mumps, and rubella virus vaccine live Subcutaneous, Intramuscular
- Lenvatinib Mesylate-Measles, mumps, rubella and varicella (MMRV) vaccine
- Lenvatinib Mesylate-Measles, Mumps, Rubella, and Varicella Virus Vaccine
- Measles virus vaccine, live Subcutaneous-Lenvima
- Measles virus vaccine, live Subcutaneous-Lenvima (14 MG Daily Dose)
- Measles virus vaccine, live Subcutaneous-Lenvima (18 MG Daily Dose)
- Measles virus vaccine, live Subcutaneous-Lenvima (20 MG Daily Dose)
- Measles virus vaccine, live Subcutaneous-Lenvima (24 MG Daily Dose)
- Measles virus vaccine, live Subcutaneous-Lenvima (8 MG Daily Dose)